Aktie LUCKYCOM INC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Luckycom Inc OTC Bulletin Board

Aktien

US54959R1086

Schlusskurs OTC Bulletin Board
Andere Börsenplätze
- USD - Intraday Chart für Luckycom Inc
2021 Luckwel Pharmaceuticals Inc. meldet Ergebnis für das erste Quartal zum 30. Juni 2020 CI
2021 Luckwel Pharmaceuticals Inc. berichtet über die Ergebnisse für das am 31. März 2020 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
LUCKWEL PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
LUCKWEL PHARMACEUTICALS : Changes in Registrant's Certifying Accountant, Non-Reliance on Previous Financials, Audits or Interim Review, Financial Statements and Exhibits (form 8-K/A)
LUCKWEL PHARMACEUTICALS INC. : Changes in Registrant's Certifying Accountant, Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)
LUCKWEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
LUCKWEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020
LUCKWEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended March 31, 2020
LUCKWEL PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.075 million in funding from Bounty Company Limited
LUCKWEL PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Luckwel Pharmaceuticals Inc. announced that it expects to receive $0.12 million in funding
LUCKWEL PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement (form 8-K)
LUCKWEL PHARMACEUTICALS INC. : Unregistered Sale of Equity Securities (form 8-K)
LUCKWEL PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement (form 8-K)
LUCKWEL PHARMACEUTICALS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
LUCKWEL PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities (form 8-K)
LUCKWEL PHARMACEUTICALS INC. : Other Events (form 8-K)
Luckwel Pharmaceuticals Inc. Announces Address Changes
Luckwel Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2019
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. LWEL Aktie
  4. Aktie
  5. Nachrichten Luckycom Inc
  6. Andere Sprachen